ft 07 apr 94 technolog cure risk set manufactur plant particular gambl drug compani biotechnolog compani cross peril line pure research develop manufactur move could lead graveyard strong root scienc academia often littl experi product even astut compani troubl assess much invest manufactur facil chiron us biotechnolog compani last year receiv approv betaseron multipl sclerosi drug develop jointli schere germani fail build suffici manufactur facil accommod demand drug face repeat shortag extrem synergen centocor invest manufactur drug later reject us food drug administr fine balanc act pull say ami factor vice presid immunomed start expand research laboratori manufactur plant still approv cancer imag product walk tightrop creat uncertainti know whether drug get approv demand option make life difficult us biotechnolog group fda regul specifi drug must manufactur way prepar clinic trial process veer origin cours approv product may revok result restrict firm often sink million dollar call risk money manufactur facil may never need sometim gambl pay amgen instanc invest million dollar plant epogen red blood cell stimul prior clearanc fda start invest facil even obtain data human trial say denni fenton senior vice presid charg sale encourag enough earli trial optimist ad dilemma fact manufactur plant accommod specif type product construct facil bacteria base product exampl help much compani later discov drug base mammalian cell compani seek gain flexibl facil handl one type drug california base giant amgen put million dollar fda approv multi purpos facil fda realli like multi purpos facil say fenton show train staff sophist equip chanc mix drug small compani look resolv manufactur troubl contract product elimin need invest money front rais number risk concern proprietari right say ken bate head sale biogen use unnam group put hirulog anti coagul process enhanc part patent belong biotech firm manufactur biogen turn outsid manufactur hirulog bigger molecul usual dealt therefor could produc facil drug pitfal involv contract one thing mani compani wari hand much inform potenti competitor relationship also establish earli prior fda approv ensur clearanc drug endang anoth risk manufactur partner may later decid stop put drug leav patent holder way get product market despit concern lure contract manufactur strong british compani celltech say good busi contract product side soon open new us manufactur facil new hampshir stay busi follow strict rule say iain ross presid celltech biolog first question breach confidenti us strict chines wall research side compani competit manufactur custom receiv inform drug make group commit manufactur product outsid firm also taken serious research develop side want us make drug abid rule group say david jackson vice presid us oper celltech mean reserv capac ahead time capac avail go wait list may way minimis risk contract product made sure partner interest drug well trust good job explain bate mani group howev appeal build facil overwhelm shini new manufactur plant often seen statu symbol industri sign compani come age moreov manufactur plant give group full control qualiti output besid risk associ fda approv compani face hurdl build facil one seriou obstacl sever shortag manag worker experi make biotechnolog product mani compani move research manufactur necessari manag skill hand say william young senior vice presid genentech invest heavili manufactur facil hire peopl experi prohibit expens smaller firm yet young conced mani compani may choic number compani capabl produc drug other limit us facil like genentech usual busi make product explain start biotechnolog firm face cash constraint limit abil recruit best peopl uncertainti drug approv particularli vulner inde move manufactur may one difficult problem industri face move manufactur tremend challeng biotechnolog compani even begun address say factor mani make break decis